The State of Weight Loss Drugs
In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How weight loss drugs actually work, and how big-name prescriptions differ from each other.
We went blind after using weight-loss drugs like Ozempic and Mounjaro
I had no idea this could happen. I wouldn’t have done it,” New Jersey-based former Mounjaro user James Norris, who is now visually impaired, told The Post
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight-loss drug Wegovy.
Novo Nordisk shares fall on latest trial results for new obesity drug
Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest obesity drug from the manufacturer of blockbuster treatments Ozempic and Wegovy. The trial of CagriSema in patients who were obese or overweight and with type 2 diabetes failed to show a clear superiority to a drug from rival Eli Lilly,
Novo Nordisk shares slide 6% after weight loss drug trial disappoints
Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, helped obese or overweight adult patients with type 2 diabetes reduce their weight by 15.
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk drug yields 15.7% weight loss in phase 3 trial
Discover the latest experimental obesity drug from Novo Nordisk, achieving 15.7% weight loss after 68 weeks, which fell short of the company's expectations.
Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says
Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.
BioSpace1d
GLP-1 Side Effects Only One Factor Driving Patient Discontinuation Rates
While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...
CNET on MSN3d
GLP-1 Meds Like Ozempic: Know Potential Benefits, Risk Factors and Overdose Info
What are GLP-1 agonists? GLP-1 agonists, also known as incretin mimetics, are a class of medication that is primarily used to ...
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Terns Pharmaceuticals is a small-cap biotech with a couple of weight loss candidates in its pipeline. The stock's price ...
FOX 13 Utah4d
We're setting the record straight on some of the most common myths of GLP-1-medications
GLP-1 medications have become a popular tool for weight loss and metabolic health, but with their rise in popularity, ...
Bellevue Reporter13d
How TMates GLP-1 Weight Loss Works: The Doctor-Approved Plan That Comes to Your Door
One such revolutionary approach is the TMates GLP-1 weight loss program. TMates is a comprehensive, doctor-approved weight loss service that provides medically supervised weight loss ...
Juneau Empire11d
Can GLP-1 Medications Really Help You Lose Weight? A Look at ShedRx’s Approach
ShedRx, a telehealth provider specializing in personalized weight-loss solutions, has emerged as a leading platform offering GLP-1-based weight management programs. This blog post explores the ...
The Simple, Convenient, and Affordable Weight Loss Solution for Women
One popular option, Weight Loss by Hers, is a holistic program personalized for you. The program features four pillars of ...
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...